Lupin launches Bumetanide Injection USP in US

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US

Emcure Pharma’s SAKHI - Diabetes awareness program makes to Asia Book of Records

Indegene announces new Center in Hyderabad

With 6 operation hubs and 18 offices across North America, Europe, and Asia, Indegene’s client base includes the world’s top 20 biopharma companies

CPHI India reports surge in exhibitor numbers

Modernization and supply chain diversity drive new growth

Shilpa Pharma Lifesciences received CEP from EDQM for API, Octreotide

Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis

Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer

Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years

Sanofi invests €40 million to strengthen antibody bioproduction in France

Blenrep shows overall survival benefit in DREAMM-7 phase III trial for relapsed/refractory multiple myeloma

Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex

Natco Pharma appoints Madhava Rao Karicherla as Associate VP – Formulation Research & Development

He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University

Wanbury Q2 FY25 revenue at Rs. 161.2 crore, up 11.6%

EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24